Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.
10.1097/CM9.0000000000001560
- Author:
Ying CHENG
1
;
Hui LI
2
;
Liang ZHANG
1
;
Jing-Jing LIU
1
;
Chang-Liang YANG
1
;
Shuang ZHANG
1
Author Information
1. Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, Jilin 130012, China.
2. Translational Oncology Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, Jilin 130012, China.
- Publication Type:Review
- MeSH:
B7-H1 Antigen;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Drug Combinations;
Humans;
Immune Checkpoint Inhibitors;
Immunotherapy;
Lung Neoplasms/drug therapy*
- From:
Chinese Medical Journal
2021;134(15):1780-1788
- CountryChina
- Language:English
-
Abstract:
In recent years, immune checkpoint inhibitors (ICIs) have made breakthroughs in the field of lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor monotherapy was the first to break the treatment pattern for non-small cell lung cancer (NSCLC). However, owing to the limited benefit of ICI monotherapy at the population level and its hyper-progressive phenomenon, it may not meet clinical needs. To expand the beneficial range of immunotherapy and improve its efficacy, several research strategies have adopted the use of combination immunotherapy. At present, multiple strategies, such as PD-1/PD-L1 inhibitors combined with chemotherapy, anti-angiogenic therapy, cytotoxic T-lymphocyte-associated protein 4 inhibitors, and radiotherapy, as well as combined treatment with new target drugs, have been evaluated for clinical practice. To further understand the current status and future development direction of immunotherapy, herein, we review the recent progress of ICI combination therapies for NSCLC.
